The discovery of angiotensin-converting enzyme homologue, ACE2, added further complexity to the main axis of the RAAS, in which Ang II and its forming enzyme ACE play major roles [9, 10] . A growing body of evidence points to a possible promising role for this new member of the RAAS by opposing to the effects of the main axis [11, 12] . ACE2 has dramatically changed the direction of cardiovascular and renal research in view of the pivotal role of this enzyme in the regulation of the RAAS [12, 13] .